BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today the appointment of a Scientific Advisory Board (SAB) for MDRNA, Inc., its wholly-owned subsidiary for the development of RNAi technology and therapeutics. The SAB, initially comprised of three noted scientists and clinicians, will provide critical scientific and medical input on MDRNA’s strategic direction.
